Loss to follow-up among adults with drug-resistant TB in Papua New Guinea.

IF 1.3 Q4 RESPIRATORY SYSTEM Public Health Action Pub Date : 2024-09-01 DOI:10.5588/pha.24.0004

F Charles, Y D Lin, J Greig, S Gurra, R Morikawa, S M Graham, A Maha

{"title":"Loss to follow-up among adults with drug-resistant TB in Papua New Guinea.","authors":"F Charles, Y D Lin, J Greig, S Gurra, R Morikawa, S M Graham, A Maha","doi":"10.5588/pha.24.0004","DOIUrl":null,"url":null,"abstract":"Setting: Multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) is now endemic in the National Capital District (NCD), Papua New Guinea. Loss to follow-up (LTFU) is a challenge.Objective: To evaluate and identify risk factors for LTFU, including pre-treatment LTFU, in adults with MDR/RR-TB at Port Moresby General Hospital (PMGH).Design: A retrospective analysis of treatment initiation in adults diagnosed with MDR/RR-TB (2018-2022) and outcomes for a cohort treated for MDR/RR-TB (2014-2019). We assessed the factors associated with LTFU using multivariate logistic regression.Results: Of 95 patients diagnosed with MDR/RR-TB at PMGH from 2018 to 2022, 21 (22%) were lost to follow-up before treatment. Of the 658 adults who initiated treatment for MDR/RR-TB at PMGH from 2014 to 2019, 161 (24%) were lost to follow-up during treatment. A higher proportion of patients on injectable-containing long regimens (110/404, 27%) were lost to follow-up than those on the all-oral regimen containing bedaquiline (13/66, 12%). Treatment loss to follow-up was associated with age (35-54 years age group: aOR 0.49, 95% CI 0.32-0.77; 55-75 years age group: aOR 0.42, 95% CI 0.19-0.90; compared to the 15-34 years age group), residence outside of NCD (aOR 1.79, 95% CI 1.04-3.06), and year of treatment initiation.Conclusion: Pre-treatment LTFU requires programmatic focus. Shorter oral regimens and decentralised services may address the reasons for higher LTFU in younger people and people living outside NCD.","PeriodicalId":46239,"journal":{"name":"Public Health Action","volume":"14 3","pages":"85-90"},"PeriodicalIF":1.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373746/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Action","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/pha.24.0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Setting: Multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) is now endemic in the National Capital District (NCD), Papua New Guinea. Loss to follow-up (LTFU) is a challenge.

Objective: To evaluate and identify risk factors for LTFU, including pre-treatment LTFU, in adults with MDR/RR-TB at Port Moresby General Hospital (PMGH).

Design: A retrospective analysis of treatment initiation in adults diagnosed with MDR/RR-TB (2018-2022) and outcomes for a cohort treated for MDR/RR-TB (2014-2019). We assessed the factors associated with LTFU using multivariate logistic regression.

Results: Of 95 patients diagnosed with MDR/RR-TB at PMGH from 2018 to 2022, 21 (22%) were lost to follow-up before treatment. Of the 658 adults who initiated treatment for MDR/RR-TB at PMGH from 2014 to 2019, 161 (24%) were lost to follow-up during treatment. A higher proportion of patients on injectable-containing long regimens (110/404, 27%) were lost to follow-up than those on the all-oral regimen containing bedaquiline (13/66, 12%). Treatment loss to follow-up was associated with age (35-54 years age group: aOR 0.49, 95% CI 0.32-0.77; 55-75 years age group: aOR 0.42, 95% CI 0.19-0.90; compared to the 15-34 years age group), residence outside of NCD (aOR 1.79, 95% CI 1.04-3.06), and year of treatment initiation.

Conclusion: Pre-treatment LTFU requires programmatic focus. Shorter oral regimens and decentralised services may address the reasons for higher LTFU in younger people and people living outside NCD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

巴布亚新几内亚成人耐药结核病患者失去随访机会。

背景：巴布亚新几内亚国家首都区（NCD）目前流行耐多药/耐利福平结核病（MDR/RR-TB）。失去随访（LTFU）是一项挑战：评估并确定莫尔兹比港总医院（PMGH）MDR/RR-TB成人患者LTFU（包括治疗前LTFU）的风险因素：对确诊为MDR/RR-TB成人患者的治疗启动情况（2018-2022年）和MDR/RR-TB治疗队列的治疗结果（2014-2019年）进行回顾性分析。我们使用多变量逻辑回归评估了与LTFU相关的因素：2018年至2022年在PMGH确诊为MDR/RR-TB的95名患者中，有21人（22%）在治疗前失去随访。2014年至2019年在PMGH接受MDR/RR-TB治疗的658名成人中，有161人（24%）在治疗期间失去了随访。与使用含有贝达喹啉的全口服治疗方案的患者（13/66，12%）相比，使用含有注射剂的长效治疗方案的患者（110/404，27%）失去随访的比例更高。随访治疗损失与年龄（35-54 岁年龄组：aOR 0.49，95% CI 0.32-0.77；55-75 岁年龄组：aOR 0.42，95% CI 0.19-0.90；与 15-34 岁年龄组相比）、NCD 以外的居住地（aOR 1.79，95% CI 1.04-3.06）和开始治疗的年份有关：结论：治疗前LTFU需要重点关注。较短的口服治疗方案和分散的服务可解决年轻人和居住在 NCD 以外地区的人群中治疗时间较长的原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Public Health Action RESPIRATORY SYSTEM-

自引率

0.00%

发文量

期刊介绍： Launched on 1 May 2011, Public Health Action (PHA) is an official publication of the International Union Against Tuberculosis and Lung Disease (The Union). It is an open access, online journal available world-wide to physicians, health workers, researchers, professors, students and decision-makers, including public health centres, medical, university and pharmaceutical libraries, hospitals, clinics, foundations and institutions. PHA is a peer-reviewed scholarly journal that actively encourages, communicates and reports new knowledge, dialogue and controversy in health systems and services for people in vulnerable and resource-limited communities — all topics that reflect the mission of The Union, Health solutions for the poor.